Darolutamide Improves Metastasis-Free Survival in High-Risk Prostate Cancer
Phase III trial reveals significant reduction in metastasis risk for high-risk prostate cancer patients.
1Phase III Trial Results
The DASL-HiCaP phase III trial demonstrated that adding darolutamide to androgen deprivation therapy and radiation significantly improves outcomes. Patients with very high-risk prostate cancer showed a 95% metastasis-free survival rate at four years. This compares to an 88% rate in the placebo group, representing a 58% reduction in the risk of metastasis.
2Defining Very High Risk
The study utilized specific criteria to define very high-risk patients, distinct from other trials like STAMPEDE. For primary radiation therapy, eligibility included grade group 5 or pelvic lymph node disease. Patients with grade group 4 required additional factors like a PSA level over 20 or clinical T2b stage to qualify for participation.
3Salvage Therapy Criteria
Participants receiving salvage radiation therapy after radical prostatectomy were included if their PSA remained persistent or rose within 12 months. Eligibility also required grade group 5 or clinical pelvic lymph node involvement. Those with grade group 4 were eligible if they presented with pathological T3a or higher, ensuring a strictly high-risk study population.
4Standardized Treatment Protocols
All participants received contemporary doses of radiation and hormonal therapy to ensure a robust baseline. Primary settings utilized doses of 78 Gy or higher, while salvage settings used 64 Gy or higher. Pelvic radiation therapy was mandatory for all patients, allowing researchers to isolate the specific therapeutic impact of adding the drug darolutamide.
5Clinical Safety Profile
Safety results indicated that the addition of darolutamide did not introduce new emergent toxicities compared to the placebo group. Notably, there was no observed increase in cardiovascular toxicity. The adverse event profiles remained similar across both study arms, suggesting that the intensified treatment regimen is well-tolerated by this specific patient population.
6Imaging Methodology Used
The study measured metastasis-free survival using conventional imaging techniques rather than PSMA-based imaging. This distinction is critical for interpreting the trial data, as it establishes a clear benchmark for clinical practice. By relying on conventional imaging, the findings provide a standardized metric for assessing recurrence risk in patients with very high-risk disease.
7Practice-Changing Potential
Investigator Tamim Niazi describes the findings as practice-changing for oncology. By significantly reducing the risk of metastasis, the combination therapy establishes a new treatment pathway for patients facing a high probability of relapse. These results offer a clear clinical strategy for managing patients who previously had limited options for preventing disease progression.
8Future Clinical Implications
The DASL-HiCaP trial provides evidence that treatment intensification is effective for high-risk prostate cancer patients. By achieving a hazard ratio of 0.48, the study confirms that darolutamide serves as a potent intervention. Clinicians can now utilize these data to better tailor treatment plans for patients at the highest risk of systemic disease.